The Hidden Economics of Antibiotics: Access, Innovation, and a Push for Global Solutions

Antibiotics are essential yet financially fragile. This episode of Discovery examines why pharmaceutical companies struggle to profit from new antibiotics, how the market drives bankruptcy even after approval, and how funders and researchers are experimenting with new business models to keep life-saving drugs available worldwide. Through interviews with industry leaders and advocates, the podcast reveals the tension between innovation, access, and responsible use, and highlights emerging approaches that link investment to sustained patient access rather than immediate sales. The narrative follows the Beam Alliance, Achaogen, Paratek, Basilea, GardP, CarbX, and BugWorks, and discusses the UK subscription model and broader efforts to fix the AMR market for the public good.

Overview

The podcast explores a crisis at the heart of modern medicine: the economic model for antibiotics is badly broken, leaving companies unable to sustain development even after regulatory approval. It traces a thread from early attempts at new antibiotic discovery to the collapse of several ventures, and it emphasizes how antimicrobial resistance creates a moving target: we need better drugs, but doctors and patients must use them judiciously to avoid resistance. The discussion frames antimicrobial resistance as a global health threat that demands innovative financing and governance, not just scientific breakthroughs. "Antibiotics have value to society, they’re like insurance policies, they’re like infrastructure, bridges and tunnels" - John Rex (AMR News)

"The trick is that antibiotics have a value that is different from other kinds of drugs. If you’ve got high blood pressure, you take a daily pill for years; antibiotics are used briefly and sparingly, which makes the economics unattractive to investors" - Kevin Outerson (Carb-X)

The Economics of Antibiotics

The central tension is laid bare: antibiotics cure infections quickly and are often cheap once generic, yet the initial development and late-stage trials are prohibitively expensive. This mismatch prompts bankruptcy or near-collapse for biotech firms that finally reach approval. The podcast examines how this reality has shaped investment patterns and led to a reliance on government support and philanthropic funding. It also highlights a growing conviction that new models are needed—models that reward access and stewardship, not just sales volumes. The UK’s subscription approach is presented as a potential blueprint, paying upfront for access to new antibiotics to stabilize the market over a decade.

"Antibiotics have value to society, they have to be paid for as a public good, not just as a product" - Kevin Outerson (Carb-X)

Case Studies: Achaogen and Paratek

The episode moves from theory to practice by profiling Achaogen, whose ambitious drug Plazomycin finally faced a market that could not sustain the business. It contrasts this with Paratek, a company that managed to stay afloat by adopting a lean, capital-efficient launch and relying on partnerships to handle sales, thereby keeping the product available to patients while managing cash flow. The contrasting trajectories illustrate how different corporate strategies interact with a volatile market defined by antibiotic stewardship, reimbursement, and manufacturing costs.

"We launched our product with 20 sales representatives because that’s what we could afford. As revenues grew, we added more, but profitability needed time" - Evan Lowe (Paratek CEO)

Global Access and New Models: GardP, Beam Alliance, and BugWorks

Looking beyond a single company, the podcast spotlights global initiatives aimed at expanding access to new antibiotics in the Global South. GARDP’s role in supporting late-stage trials and reformulating business incentives is examined, along with Beam Alliance’s efforts to unite small firms under a shared policy voice to attract investors. The interview with Anand Kumar of BugWorks introduces a bold vision: launch first in high-burden markets like India and Southeast Asia, build robust real-world evidence, and then scale globally. The overarching message is that responsible innovation must be paired with sustainable access, especially in LMICs where the burden of antimicrobial resistance is often greatest. "8.2 billion people on the planet, 6 billion plus live in LMICs. If most unmet need is in countries like India, why not launch first there?" - Anand Kumar (BugWorks)

"The future of antibiotics is about access as much as discovery, and about funding models that keep real-world availability front and center" - Shimas O’Brien (GARDP, Director of Research & Development)

Towards a Solveable Problem

The episode closes by acknowledging that revamping the economics of antibiotics will take time, but outlines practical steps: diversify funding sources, de-risk late-stage clinical trials through non-dilutive funding, and implement policy instruments such as a Netflix-like subscription to keep essential antibiotics available while stewardship programs ensure sustainable use. The discussion emphasizes that the value of antibiotics extends far beyond individual patients, preserving the integrity of modern medicine itself.

"Antibiotics have value to society. They’re like insurance policies, they’re like infrastructure, like bridges and tunnels. If we fix the market, we fix the future of medicine" - Roland Pease (Host)